NCT04276870RecruitingPhase 2
CD19-Directed Chimeric Antigen Receptor CD19 Redirected Autologous T Cells (CART19) for Orphan Indications of Pediatric B Cell Acute Lymphoblastic Leukemia (B ALL)
Stephan Grupp MD PhD2 sites in 1 country133 target enrollmentStarted: March 12, 2020Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Sponsor
- Enrollment
- 133
- Locations
- 2
- Primary Endpoint
- Event-free survival (EFS)
Study Overview
Brief Summary
This is an open-label, four-cohort, phase 2 study to determine the efficacy of CART19 in pediatric and young adult patientswith hypodiploid (Cohort A) or t(17;19) B-ALL (Cohort B), infants with very high risk KMT2A B-ALL (Cohort C), and in patients with central nervous system (CNS) relapse who did not receive cranial radiation (XRT) or bone marrow transplantation (BMT) (Cohort D).
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 0 Years to 29 Years (Child, Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Signed informed consent form must be obtained prior to any study procedure.
- •Male and female patients with documented CD19+ B-ALL
- •a.Cohort A & B: Patients, regardless their response to initial or relapsed B ALL therapy, with the following characteristics: i.Cohort A: Subjects with confirmation of a hypodiploid karyotype (chromosome number fewer than 45) ii.Cohort B: Subjects with cytogenetic confirmation of the chromosomal translocation t(17;19) (Cohort B) b.Cohort C: Infants w/ newly diagnosed KMT2A rearranged B-ALL classified as very high risk by the following criteria: i.Age < 3 months at diagnosis ii.Age < 6 months and WBC > 300,000x109/L at diagnosis or a poor prednisone response in induction iii.MRD positive > 0.01 (or PCR > 104) after 2 courses of standard infant ALL therapy.
- •c.Cohort D: Subjects in a first or greater CNS relapse, prior to therapy with cranial XRT or HSCT for the current relapse
- •Documentation of CD19 tumor expression in bone marrow, peripheral blood, CSF, or tumor tissue.
- •Age 0 to 29 years
- •Adequate organ function defined as:
- •A serum creatinine based on age/gender as follows:
- •Maximum Serum Creatinine (mg/dL) Age Male Female 0 to < 2 years 0.6 0.6 2 to < 6 years 0.8 0.8 6 to < 10 years 1.0 1.0 10 to < 13 years 1.2 1.2 13 to < 16 years 1.5 1.4
- •≥ 16 years 1.7 1.4
- •Adequate liver function:
- •i.ALT≤ 5 x ULN; ALT ii.Total bilirubin ≤ 3 x ULN iii.ALT and/or bilirubin results that exceed this range are acceptable if, in the opinion of the physician-investigator (or as confirmed by liver biopsy), the abnormalities are directly related to ALL infiltration of the liver.
- •c.Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and < Grade 3 hypoxia; DLCO ≥ 40% (corrected for anemia) if PFTs are clinically appropriate as determined by the physician-investigator.
- •d.Left Ventricular Shortening Fraction (LVSF) ≥ 28%, or Left Ventricular Ejection Fraction (LVEF) ≥ 45% by echocardiogram. In cases where quanitative assessment of LVSF/LVEF is not possible, a statement by the cardiologist that the ECHO shows qualititatively normal ventricular function wll suffice.
- •Adequate performance status defined as Lansky or Karnofsky score ≥ 50
- •Subjects of reproductive potential must agree to use acceptable birth control methods
Exclusion Criteria
- •For subjects with a CNS relapse, prior cranial XRT or BMT for the current relapse is an exclusion.
- •Active hepatitis B or active hepatitis C.
- •HIV Infection.
- •Active acute or chronic graft-versus-host disease (GVHD) requiring systemic therapy.
- •Concurrent use of systemic steroids at the time of cell infusion or cell collection, or a condition, in the treating physician's opinion, that is likely to require steroid therapy during collection or after infusion. Steroids for disease treatment at times other than cell collection or at the time of infusion are permitted. Use of physiologic replacement hydrocortisone or inhaled steroids is permitted as well.
- •CNS3 disease that is progressive on therapy, or with CNS parenchymal lesions that might increase the risk of CNS toxicity.
- •Pregnant or nursing (lactating) women.
- •Uncontrolled active infection.
Arms & Interventions
Subjects with hypodiploid B-ALL
Experimental
Intervention: Murine CART19 (Biological)
Subjects with t(17;19) B-ALL
Experimental
Intervention: Murine CART19 (Biological)
Infant subjects with very high risk KMT2A B-ALL
Experimental
Intervention: Murine CART19 (Biological)
Subjects with central nervous system (CNS) relapse
Experimental
who did not receive cranial radiation (XRT) or bone marrow transplantation (BMT)
Intervention: Murine CART19 (Biological)
Outcomes
Primary Outcomes
Event-free survival (EFS)
Time Frame: One year
1 year event-free survival (EFS), where events include no response, relapse, death due to any cause
Secondary Outcomes
- EFS Rate 1(One year)
- To further evaluate the safety of CART19 in the target patient populations(One year)
- EFS rate 2(One year)
- Relapse Free survival 4(One year)
- MRD conversion(One year)
- Relapse Free survival 2(One year)
- Relapse Free survival 1(One year)
- Relapse Free survival 3(One year)
Investigators
Stephan Grupp MD PhD
Director, Cancer Immunotherapy Program
Children's Hospital of Philadelphia
Study Sites (2)
Loading locations...
Similar Trials
Recruiting
Phase 2
Treatment of CD19 Chimeric Antigen Receptor T Cells for Pediatric Patients With CD19-positive B-cell Acute Lymphoblastic Leukemia Who Are Indicated for Hematopoietic Stem Cell TransplantationCD19 CAR-T TherapyVery High Risk Acute Lymphoblastic LeukemiaNCT06247501Seoul National University Hospital50
Recruiting
Phase 2
Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell LymphomaRecurrent Mantle Cell LymphomaRefractory Mantle Cell LymphomaNCT04484012City of Hope Medical Center36
Recruiting
Phase 1
Clinical Trial of CD19-targeted CAR-T Therapy for Refractory Juvenile DermatomyositisJuvenile DermatomyositisNCT06569472Chongqing Precision Biotech Co., Ltd10
Recruiting
Phase 1
CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children.Acute Lymphoblastic LeukemiaNCT06752785Guangzhou Women and Children's Medical Center10
Unknown
Phase 1
Phase I Study of CD19-CAR-T2 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Acute LeukemiaAcute LeukemiaNCT02822326Guangdong Provincial People's Hospital30